Incyte (INCY) Tops Q2 EPS by 6c; Raises Jakafi Sales Guidance
Get Alerts INCY Hot Sheet
Price: $126.75 -0.98%
EPS Growth %: -225.2%
Financial Fact:
Contract revenues: 3.21M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -225.2%
Financial Fact:
Contract revenues: 3.21M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $162.98 million versus the consensus estimate of $153.27 million.
For the quarter ended June 30, 2015, net product revenues of Jakafi were $142 million as compared to $84 million for the same period in 2014, representing 69 percent growth
Sees FY 2015 Jakafi net product revenues of $560-$575 million versus the prior guidance of $525-$565 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- BlackRock’s Rosenberg says inflation data key after jobs beat
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share